BridgeBio Pharma
CA - Palo AltoPharmaceutical
Focus: BridgeBio Pharma is a Palo Alto-based pharmaceutical company focused on genetic disease treatments, with particular strength in rare diseases and oncology. The company operates a diversified pipeline spanning rare genetic disorders, amyloidosis, and oncology indications.
Profile data last refreshed 53m ago · AI intelligence enriched 1mo ago
Open Jobs
100+9 this month
Growing — net +9 jobs in 30d
62 jobs added vs 53 removed. Steady team buildout.
Should You Work at BridgeBio Pharma?
AI assessmentBest fit for commercial-track and late-stage clinical professionals; research scientists should clarify funding and headcount trajectory before joining.
Why Work Here
- One approved product (ATTRUBY/acoramidis) generating revenue with 2039 LOE provides near-term financial stability and commercial scaling opportunities.
- Heavy hiring skew toward Commercial (60/96 roles) signals aggressive market development phase—strong visibility for sales, marketing, and field roles.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Growing
Growth13.0yr
First and only approved product; long exclusivity runway to 2039 provides 15-year revenue foundation.
Help build intelligence for BridgeBio Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.